TABLE 3.
Demographic, clinical and immunological characteristics of patients at baseline
| ALL | Data (n) | CSM | Data (n) | MAH | Data (n) | TM | Data (n) | |
|---|---|---|---|---|---|---|---|---|
| Male (n, %) | 259 (27%) | 960 | 198 (28.9%) | 684 | 45 (26.9%) | 167 | 16 (14.7%) | 109 |
| Age (years, median, IQ) | 36 (28–75) | 960 | 36 (28–72) | 32 (27–75) | 38 (26–68) | |||
| Pregnancy (n. %) | 96 (13.7%) | 701 | 66 (13.6%) | 486 | 24 (19.7%) | 122 | 6 (6.5%) | 93 |
| Education (n, %) | ||||||||
| None | 166 (21.6%) | 768 | 138 (24.2%) | 571 | 4 (3.5%) | 114 | 24 (28.9%) | 83 |
| Secondary or more | 254 (33.1%) | 768 | 188 (32.9%) | 571 | 48 (42.1%) | 114 | 18 (21.7%) | 83 |
| WHO status (n, %) | ||||||||
| WHO I | 581 (61.8%) | 940 | 349 (52.5%) | 665 | 147 (88.6%) | 166 | 85 (78%) | 109 |
| WHO II | 220 (23.4%) | 940 | 189 (28.4%) | 665 | 13 (7.8%) | 166 | 18 (16.5%) | 109 |
| WHO III/IV | 139 (14.8%) | 940 | 127 (19.1%) | 665 | 6 (3.6%) | 166 | 6 (5.5%) | 109 |
| CD4+ T cells (n cell/ml) (median, IQ) | 309 (156–510) | 894 | 308 (140–494) | 654 | 320 (203–562 | 133 | 306 (185–555) | 107 |
| CD4+ T cells <200 cell/ml (n, %) | 283 (31.7%) | 894 | 221 (33.8%) | 654 | 33 (24.8%) | 133 | 29 (27.1%) | 107 |
| CD4+ T cells <350 cell/ml (n, %) | 497 (55.6%) | 894 | 367 (56.1%) | 654 | 73 (54.9%) | 133 | 57 (53.3%) | 107 |
| CD4+ T cells <100 cell/ml (n, %) | 133 (14.9%) | 894 | 111 (17%) | 654 | 12 (9%) | 133 | 10 (9.3%) | 107 |
Abbreviations: CSM, Centro de Saude de Morrumbene; MAH, Centro de Saude de Mahangue; TM, TARV Movel service; WHO, World Health Organisation.